iNCOVACC

Bharat Biotech’s intranasal vaccine, BBV154 or incovacc is the world’s first intranasal vaccine to be approved as a booster dose for COVID-19.

• The nasal vaccine is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
• As the vaccine is given nasally, it triggers an immune response in the mucosal membrane.
• BBV154 may produce local antibodies in the upper respiratory tract which may provide the potential to reduce infection and transmission.
• This is the second heterologous booster to be included in the vaccination programme after Corbevax.